Abstract

The establishment of individualized chemotherapy for colorectal carcinoma based on the expression of genes involved in chemotherapeutic sensitivity or prognosis is necessary. To achieve this, the expression profiles of genes within tumors and their relationship to clinicopathological factors must be elucidated. Here, we selected 10 genes (TS, DPD, TP, FPGS, GGH, DHFR, ERCC1, TOPO-1, VEGF, and EGFR), examined differences in their mRNA expression between the upper and lower thirds of tumors by laser-captured microdissection and real-time RT-PCR (the Danenberg tumor profile), and analyzed the relationships between their expression profiles and clinicopathological factors. Interestingly, the mRNA expression of DPD, TP, and VEGF was significantly higher in the lower third than in the upper third of tumors (P = 0.044, 0.023, and 0.013, resp.). Furthermore, increased ERCC1 mRNA expression in the lower third of tumors correlated with recurrence (P = 0.049), and VEGF mRNA expression was significantly higher in cases with recurrence than in cases without recurrence, both in the upper and lower thirds of tumors (P = 0.018 and 0.036, resp.). These results implied that heterogeneity in DPD, TP, and VEGF expression may exist in colorectal carcinoma and that ERCC-1 and VEGF may be markers predicting recurrence after curative operation.

Highlights

  • 5-Fluorouracil (5-FU) and its relatives are mainstays in the chemotherapeutic treatment of colorectal carcinoma [1, 2]

  • Many studies have reported that a variety of candidates can be used to predict chemotherapeutic sensitivity or prognosis [3], and the establishment of individualized chemotherapy based on the expression profiles of these genes is necessary for promoting the efficacy of chemotherapeutic agents in both nonresponders and responders

  • For genes other than DPD, TP, and VEGF, there were no differences in mRNA expression levels between the upper and lower thirds of the tumors

Read more

Summary

Introduction

5-Fluorouracil (5-FU) and its relatives are mainstays in the chemotherapeutic treatment of colorectal carcinoma [1, 2]. Many studies have reported that a variety of candidates can be used to predict chemotherapeutic sensitivity or prognosis [3], and the establishment of individualized chemotherapy based on the expression profiles of these genes is necessary for promoting the efficacy of chemotherapeutic agents in both nonresponders and responders. Low expression levels of both TS and TP in tumors predict very high response rates to 5-FU as well as significantly longer survival times [10]. We examined differences in the mRNA expression of these genes between the upper and lower thirds of colorectal tumors and analyzed the relationships between their expression profiles and clinicopathological factors

Materials and Methods
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call